Pembrolizumab-Associated Stevens-Johnson Syndrome in a Patient With Metastatic Non-small Cell Lung Cancer: A Case Report.
cancer immunotherapy
dermato-oncology
metastatic non-small cell lung cancer
pembrolizumab cutaneous side effect
stevens-johnson syndrome
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
06
07
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Pembrolizumab is a monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and is approved for the treatment of several malignancies. We present a rare case of Stevens-Johnson syndrome (SJS) occurring in a 75-year-old female 14 days after receiving the first dose of pembrolizumab therapy to treat stage IV non-small cell carcinoma of the lungs with metastasis to the brain. Although pruritus and papular, erythematous rashes are documented after its use, severe reactions such as SJS and toxic epidermal necrolysis (TEN) are rarely seen in clinical practice. In addition to supportive care, the patient also received intravenous immunoglobulin (IVIG) and corticosteroid therapy and responded well to the therapy. Nearly complete re-epithelialization was achieved four weeks after the start of skin lesions. This case highlights a rare phenomenon of SJS- and TEN-associated adverse reactions following treatment with pembrolizumab.
Identifiants
pubmed: 37546048
doi: 10.7759/cureus.41439
pmc: PMC10403812
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e41439Informations de copyright
Copyright © 2023, Sandhu et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Arch Dermatol. 2003 Jan;139(1):26-32
pubmed: 12533160
J Invest Dermatol. 2000 Aug;115(2):149-53
pubmed: 10951229
Curr Probl Cancer. 2020 Apr;44(2):100478
pubmed: 31122669
Oxf Med Case Reports. 2022 Mar 16;2022(3):omac025
pubmed: 35317001
Am J Dermatopathol. 2020 Apr;42(4):292-296
pubmed: 31567395
J Dermatol. 2015 Jan;42(1):42-8
pubmed: 25355273
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620914796
pubmed: 32207346
J Oncol Pharm Pract. 2020 Jul;26(5):1259-1265
pubmed: 31810421